NYSE:GSK - GlaxoSmithKline Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.76 +1.15 (+2.90 %)
(As of 10/19/2018 03:38 PM ET)
Previous Close$39.61
Today's Range$40.09 - $40.90
52-Week Range$34.52 - $42.36
Volume260,810 shs
Average Volume2.17 million shs
Market Capitalization$98.55 billion
P/E Ratio14.18
Dividend Yield4.94%
Beta0.87
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; and a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GSK
CUSIPN/A
Phone44-20-8047-5000

Debt

Debt-to-Equity Ratio8.13
Current Ratio0.94
Quick Ratio0.61

Price-To-Earnings

Trailing P/E Ratio14.18
Forward P/E Ratio13.77
P/E Growth1.94

Sales & Book Value

Annual Sales$38.89 billion
Price / Sales2.60
Cash Flow$3.9382 per share
Price / Cash10.35
Book Value$1.81 per share
Price / Book22.52

Profitability

EPS (Most Recent Fiscal Year)$2.88
Net Income$1.97 billion
Net Margins5.51%
Return on Equity159.74%
Return on Assets10.40%

Miscellaneous

Employees99,349
Outstanding Shares2,479,930,000
Market Cap$98.55 billion

GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Wednesday, July 25th. Shareholders of record on Friday, August 10th will be given a dividend of $0.496 per share on Thursday, October 11th. This represents a $1.98 annualized dividend and a yield of 4.87%. The ex-dividend date is Thursday, August 9th. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) issued its earnings results on Wednesday, July, 25th. The pharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts' consensus estimates of $0.71 by $0.06. The pharmaceutical company earned $9.95 billion during the quarter, compared to analyst estimates of $9.47 billion. GlaxoSmithKline had a net margin of 5.51% and a return on equity of 159.74%. View GlaxoSmithKline's Earnings History.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, October 31st 2018. View Earnings Estimates for GlaxoSmithKline.

What price target have analysts set for GSK?

16 analysts have issued twelve-month target prices for GlaxoSmithKline's shares. Their predictions range from $35.85 to $47.00. On average, they anticipate GlaxoSmithKline's share price to reach $40.7125 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View Analyst Price Targets for GlaxoSmithKline.

What is the consensus analysts' recommendation for GlaxoSmithKline?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:
  • Ms. Emma Walmsley, CEO & Director (Age 48)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 54)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 55)

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Aperio Group LLC (0.03%), Cornerstone Wealth Management LLC (0.02%), BB&T Corp (0.01%), Bank of Montreal Can (0.01%), Farmers Trust Co. (0.00%) and Chemung Canal Trust Co. (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including World Asset Management Inc, BB&T Corp, Pennsylvania Trust Co, Raymond James Trust N.A., Livingston Group Asset Management CO operating as Southport Capital Management, BLB&B Advisors LLC and Beacon Financial Group. View Insider Buying and Selling for GlaxoSmithKline.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was bought by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Chemung Canal Trust Co., Kempner Capital Management Inc., Strategic Advisors LLC, Iberiabank Corp, First Manhattan Co., Ipswich Investment Management Co. Inc. and Kiley Juergens Wealth Management LLC. View Insider Buying and Selling for GlaxoSmithKline.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $40.76.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $98.55 billion and generates $38.89 billion in revenue each year. The pharmaceutical company earns $1.97 billion in net income (profit) each year or $2.88 on an earnings per share basis. GlaxoSmithKline employs 99,349 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is http://www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]


MarketBeat Community Rating for GlaxoSmithKline (NYSE GSK)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  480 (Vote Outperform)
Underperform Votes:  834 (Vote Underperform)
Total Votes:  1,314
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe GSK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel